Marrone Bio Innovations (MBII -0.6%) FY revenue grew 23.3% Y/Y to $18.16M.
Overall FY2017 operating margin recovered by 3928 bps to -129%.
Gross margin for FY2017 increases by 42% Y/Y.
Product shipments grew 16.2%Y/Y to $19M.
Company launched 2 commercial products in 2017, Haven®, a sun protectant, and StargusTM, a biofungicide.
The company completed a series of private placement financing and debt restructuring transactions, generating ~$27.3M of proceeds and converted $45.0M of prior debt into equity in February 2018.
Previously: Marrone Bio beats by $0.03, misses on revenue (March 29)
Subscribe for full text news in your inbox